CD163 and glioma: As showed in Table 4, a significant positive correlation was observed between LYRM4-AS1 and B cell’s biomarkers (CD19 and CD79A), CD4+ T cell’s biomarkers (CD4), M1 macrophage’s biomarkers (NOS2, IRF5, and PTGS2), M2 macrophage’s biomarkers (CD163, VSIG4, and MS4A4A), neutrophil’s biomarkers (CEACAM8, ITGAM and CCR7), T cell’s biomarkers (CD2, CD3E), Th1 cell’s biomarkers (TBX21, STAT4 and TNF), Th2 cell’s biomarkers (GATA3, STAT6, STAT5A and IL13) and Th17 cell’s biomarkers (STAT3 and IL17A) in glioma.